Sensitive methods for determination of free digitoxin concentration using digitoxin immunoassays: Demonstration of elevated free digitoxin concentration caused by digitoxin-phenytoin interaction by applying these new techniques

Therapeutic Drug Monitoring

Volumn 21, Issue 6, 1999, Pages 625-630

  Dasgupta, Amitava ^a   Vega, Anita E ^a   Wells, Alice ^a   Datta, Pradip ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Chemiluminescent assay Phenytoin; Fluorescence polarization; Free digitoxin

Indexed keywords

DIGITOXIN; PHENYTOIN;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CHEMOLUMINESCENCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN BINDING; TECHNIQUE; ULTRAFILTRATION;

BINDING, COMPETITIVE; BLOOD PROTEINS; CARDIOTONIC AGENTS; CHEMILUMINESCENT MEASUREMENTS; DIGITOXIN; DRUG INTERACTIONS; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; METHANOL; PHENYTOIN; SENSITIVITY AND SPECIFICITY;

EID: 0032698989     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199912000-00008     Document Type: Article

References (15)

1. Koren G, Soldin SJ. Cardiac glycosides. Clin Lab Med 1987;7: 587-606.
2. Stone JA, Soldin SJ. An update on digoxin. Clin Chem 1989; 35: 1326-31.
3. Larsen A, Storstein L. Digitoxin kinetics and renal excretion in children. Clin Pharmacol Ther 1973; 19: 387-95.
4. Barre J, Didney F, Delion F, Tillemont JP. Problems in therapeutic drug monitoring: Free drug level monitoring. Ther Drug Monit 1988; 10: 133-43.
5. Scheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentration of drugs. In Melon KL, Morrelli HF eds. Clinical pharmacology: basic principles of therapeutics. New York: Macmillan, 1978 pp 71-109.
6. Argyl JC, Kinniburg DW, Costa R. Evaluation of an ultrafiltration-fluorescence polarization immunoassay for monitoring unbound phenytoin. Ther Drug Monit 1984;6: 117-20.
7. Shoeman DW, Azarnoff DL. The alteration of plasma proteins in uremia as reflected in their ability to bind digoxin and diphenylhydatoin. Pharmacology 1972; 7: 169-77.
8. Vanholder R, Landschoot NV, DeSmet R, Schoots AD, Ringoir S. Drug protein binding in chronic renal failure: Evaluation of nine drugs. Kidnet Int 1988; 33: 996-1004.
9. Dasgupta A, Malik S. fast atom bombardment mass spectrometric determination of molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins. Am J Nephrol 1994; 14: 162-8.
10. Fraser DG, Ludden TM, Evans RP, Sutherland EW. Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 1980; 27: 165-9.
11. Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effect. Clin Pharmacol Ther 1982; 31: 642-9.
12. Dasgupta A, Emerson L. Interaction of valproic acid with nonsteroidal anti-inflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Ther drug Monit 1996; 18: 654-59.
13. Fedler C, Stewart MJ. Plasma total phenytoin: a possibly misleading test in developing countries. Ther Drug Monit 1999; 21: 155-60.
14. Perucca E. Free level monitoring of antiepileptic drugs: clinical usefulness and case studies. Clin Pharmacokinet 1976; 1: 161-88.
15. Aass H, Johannessen SI, Osnes JB, Skomedal T, Stokke KT. Serum digitoxin in concomitant use of antiepileptics in routine therapy. Tidsskr Nor Laegeforen 1997; 117: 2032-5.